LEUCEMIA ACUTA MIELOIDE
- IRSTB082 – immune AML. Studio dell’immunogenicità e degli effetti immunologici degli agenti ipometilanti nella leucemia mieloide acuta
- ARO-013. Phase III randomized, double-blind, placebo-controlled study investigating the efficacy of the addition of Crenolanib to salvage chemotherapy alone in subjects ≤ 75 years of age with relapsed/refractory FLT3 mutated acute myeloid leukemia
- AML1819. Phase III study to assess the impact of Gemtuzumab Ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of Glasdegib as a post-transplant maintenance, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia
- Abbvie PMOS-VERO. VEnetoclax Real-World Observational study on effectivenes and treatment management in patients with newly diagnosed AML who are ineligible for intensive chemotherapy in Italy (VERO)
- AML1919. A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study
- IRST-204.08. Studio clinico IMPACT STREAM ‘’master framework for relapse or refractory acute myeloid leukemia Impact stream – a prospective observational study of treatment outcomes’’
- AC220-168 (QUANTUM-WT). A phase 3, double-blind, randomized, placebo-controlled trial of quizartinib administered in combination with induction and consolidation chemotherapy and administered as manteinance therapy in adult patients with newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia (QUANTUM-WT) (quizartinib or placebo plus chemotherapy in newly diagnosed patients with FLT3-ITD negative AML) and Clinical Performance Study Plan – FLT3-ITD fragment segment analysis by capillary electrophoresis assay
- ORAL-REAL. Oral Azacitidine Real-Life: observational study on effectiveness and management of manteinance with oral azacitidine in patients with acute myeloid leukemia in first complete remission
- ASTX030-01. A multi-phase, pharmacokinetics, safety, and efficacy study of ASTX030 (Azacitidine e Cedazurine) as monotherapy in subjects with myeloid neoplasm or in combination with venetoclax in subjects with AML or MDS
LEUCEMIA ACUTA LINFOBLASTICA
- GIMEMA LAL2418. Studio di fase IIA sulla fattibilità e l’efficacia di Inotuzumab Ozogamicin (IO) in pazienti adulti con Leucemia Linfoblastica Acuta a cellule B con Malattia Minima Residua positiva prima di un trapianto di cellule staminali ematopoietiche
- GIMEMA LAL2922. Combinazione di Ponatinib e chemioterapia come trattamento di prima linea per i pazienti con leucemia acuta linfoblastica BCR/ABL1-like (LAL BCR/ABL1-like) – BALLik
- GIMEMA LAL2820. Leucemia acuta linfoblastica Philadelphia-positiva dell’adulto alla diagnosi. Trattamento sequenziale con il ponatinib e l’anticorpo monoclonale bispecifico blinatumomab vs chemioterapia e imatinib
- GIMEMA LAL2620. Ponatinib for for the management of minimal residual disease (MDR) and hematological relapse in adult Ph+ acute lymphoblastic leukemia (PH+ALL) patients
- GIMEMA LAL2720. Advancing chemical and genomic strategies for relapsed/refractory T-ALL and ETP-ALL
- GIMEMA INF0123. Multicenter retrospective observational study analyzing infective complications and the clinical outcome of patients with acute lymphoblastic leukemia treated with Inotuzumab Ozogamic (INO-FIRTS) – Studio GIMEMA INF0123
- GIMEMA LAL3024. Daratumumab nei pazienti adulti affetti da Leucemia Acuta Linfoblastica a cellule T ad alto rischio trattata secondo il programma di trattamento nazionale delle LAL (DARATALL-VHR)- GIMEMA ALL3024
SINDROMI MIELODIPLASTICHE
- Registro MDS FISM. Registro Piemontese delle Sindromi Mielodisplastiche
- Syros SY1425. A randomized, double-blind- placebo-controlled phase 3 study of SY-1425 plus Azacitidine versus placebo plus Azacitidine in newly diagnosed, RARA-positive adult patients with higher-risk Myelodysplastic Syndrome
- QoL-ONE Phoenix. Efficacy and safety of Luspatercept for the treatment of anemia due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to prior treatments, who require red blood cell transfusion
- MAXILUS. A Phase 3b, open-label study evaluating the efficacy and safety Luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk who require RBC transfusions
- ASTX030-01. A multi-phase, pharmacokinetics, safety, and efficacy study of ASTX030 (Azacitidine e Cedazurine) as monotherapy in subjects with myeloid neoplasm or in combination with venetoclax in subjects with AML or MDS
- GLORA-4. An international, multicenter, randomized, double-blind, placebo-controlled, pivotal registration Phase III study of APG-2575 (Lisaftoclax) in combination with Azacitidine (AZA) in patients with newly diagnosed higher risk Myelodysplastic Syndrome (GLORA-4)